Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

Preliminary data confirm Flow’s ability to successfully measure neuro-effect of ketamine over 10 days reports Kernel.

← Previous
Next →
  • Medical Specialists Subscribe
  • Industry Subscribe
  • Privacy Statement
    • Cookie Policy
  • Contact
  • Medical Specialists Subscribe
  • Industry Subscribe
  • Privacy Statement
    • Cookie Policy
  • Contact
  • HOME
  • ABOUT
  • PRESS RELEASE POLICY
  • EDITORIAL
  • ADVERTISE
  • CONTACT
  • PRIVACY
  • HOME
  • ABOUT
  • PRESS RELEASE POLICY
  • EDITORIAL
  • ADVERTISE
  • CONTACT
  • PRIVACY

© 2026 All rights Reserved. Medical Device News Magazine, a Division of PTM Healthcare Marketing, Inc.